Top stories in oncology: Live coverage of San Antonio Breast Cancer Symposium, ASH Annual Meeting and Exposition
Click Here to Manage Email Alerts
Last week’s top stories in oncology were from Healio’s live coverage of the San Antonio Breast Cancer Symposium, which recently wrapped up in Texas, and the American Society of Hematology Annual Meeting and Exposition, which just concluded in Orlando.
Experts presented data supporting the benefits of several therapies for patients with metastatic HER2-positive breast cancer, the safety and efficacy of venetoclax plus ibrutinib in patients with chronic lymphocytic leukemia, and more.
Antibody-drug conjugate provides ‘unprecedented’ benefit in metastatic HER2-positive breast cancer
Phase 2 DESTINY-Breast01 study data presented at the San Antonio Breast Cancer Symposium showed that trastuzumab deruxtecan conferred durable benefit to women with heavily pretreated HER2-positive metastatic breast cancer. Read more.
Tucatinib regimen provides ‘unprecedented’ benefit in heavily pretreated HER2-positive breast cancer
The addition of tucatinib to trastuzumab and capecitabine significantly extended survival among heavily pretreated patients with HER2-positive metastatic breast cancer, according to results of an interim analysis of the randomized phase 3 HER2CLIMB trial discussed at the San Antonio Breast Cancer Symposium. Read more.
VIDEO: First-line venetoclax -ibrutinib ‘a win on all fronts’ in chronic lymphocytic leukemia
An all-oral combination of venetoclax plus ibrutinib in the front-line setting was well tolerated and associated with high rates of undetectable minimal residual disease in the blood and bone marrow of patients with chronic lymphocytic leukemia after 1 year of therapy, according to results of the phase 2 CAPTIVATE trial presented at the American Society of Hematology Annual Meeting and Exposition. Watch video.
Accelerated partial breast irradiation effectively prevents recurrence in early breast cancer
Accelerated partial breast irradiation after surgery appeared as effective as whole breast irradiation for preventing recurrence among patients with early breast cancer, according to 10-year follow-up results from the randomized phase 3 APBI IMRT Florence trial presented at San Antonio Breast Cancer Symposium. Read more.
Ado-trastuzumab emtansine extends disease-free survival in early-stage HER2-positive breast cancer
Results of the randomized phase 2 ATEMPT trial presented at San Antonio Breast Cancer Symposium showed that ado-trastuzumab emtansine extended disease-free survival compared with paclitaxel plus trastuzumab among patients with early-stage HER2-positive breast cancer. Read more.